Literature DB >> 19522653

Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome.

Angelique G S C Jansen1, Gerwin D Rodenburg, Arie van der Ende, Loek van Alphen, Reinier H Veenhoven, Lodewijk Spanjaard, Elisabeth A M Sanders, Eelko Hak.   

Abstract

BACKGROUND: The Streptococcus pneumoniae polysaccharide capsule may be related to invasive pneumococcal disease (IPD) course.
METHODS: We performed a retrospective cohort study with nationally representative surveillance data from 1075 hospitalized patients with IPD from the Netherlands from 1 June 2004 through 31 May 2006 in the prevaccination era. Serotypes were grouped according to invasive disease potential, rate of the most serious clinical syndromes of meningitis and bacteremia without focus, and case-fatality rates. Multivariable logistic regression analysis was performed to obtain odds ratios adjusted for baseline confounders for the association of serotypes and these outcomes, using the serotypes with the lowest rates as reference.
RESULTS: IPD caused by serogroups with low invasive disease potential concerned meningitis or bacteremia without focus in 22% of cases, and 74% of patients had an underlying comorbidity. For highly invasive serogroups these figures were 10% (P < .01) and 56% (P < .01). Individual serotypes varied in the relative rate by which they caused meningitis or bacteremia without focus. Compared with the reference group composed of serotypes 1, 5, 7F, 15B, 20, and 33F, the group of serotypes 3, 19F, 23A, 16F, 6B, 9N, and 18C was associated with increased case-fatality rates (group adjusted odds ratio, 2.6; 95% confidence interval, 1.5-4.7).
CONCLUSIONS: The serotype appeared to be independently associated with IPD severity in adults, which indicates that careful monitoring of IPD after implementation of conjugate vaccines is necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19522653     DOI: 10.1086/600045

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  57 in total

1.  Functional hyposplenism.

Authors:  L Kirkineska; V Perifanis; T Vasiliadis
Journal:  Hippokratia       Date:  2014-01       Impact factor: 0.471

Review 2.  The role of vaccination in preventing pneumococcal disease in adults.

Authors:  S Aliberti; M Mantero; M Mirsaeidi; F Blasi
Journal:  Clin Microbiol Infect       Date:  2014-02-22       Impact factor: 8.067

3.  Longitudinal analysis of pneumococcal antibodies during community-acquired pneumonia reveals a much higher involvement of Streptococcus pneumoniae than estimated by conventional methods alone.

Authors:  Suzan P van Mens; Sabine C A Meijvis; Henrik Endeman; Heleen van Velzen-Blad; Douwe H Biesma; Jan C Grutters; Bart J M Vlaminckx; Ger T Rijkers
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

4.  Serotype Prevalence and Penicillin-susceptibility of Streptococcus pneumoniae in Oman.

Authors:  Mubarak M Al-Yaqoubi; Kamal M Elhag
Journal:  Oman Med J       Date:  2011-01

5.  Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.

Authors:  Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

6.  Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.

Authors:  Yujia Kong; Wei Zhang; Zhiwei Jiang; Ling Wang; Chanjuan Li; Yanping Li; Jielai Xia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Acute bacterial meningitis in infants and children: epidemiology and management.

Authors:  Shruti Agrawal; Simon Nadel
Journal:  Paediatr Drugs       Date:  2011-12-01       Impact factor: 3.022

8.  Structural, Biosynthetic, and Serological Cross-Reactive Elucidation of Capsular Polysaccharides from Streptococcus pneumoniae Serogroup 16.

Authors:  Chengxin Li; Katarzyna A Duda; Pernille L Elverdal; Ian C Skovsted; Christian Kjeldsen; Jens Ø Duus
Journal:  J Bacteriol       Date:  2019-09-20       Impact factor: 3.490

9.  Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.

Authors:  Karen L Ciprero; Rocio D Marchese; Patrick Richard; Martine Baudin; Tina M Sterling; Susan B Manoff; David Radley; Jon E Stek; Benoît Soubeyrand; John D Grabenstein; Sandrine I Samson; Luwy K Musey
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

10.  Epidemiology of vaccine-preventable invasive diseases in Catalonia in the era of conjugate vaccines.

Authors:  Pilar Ciruela; Ana Martínez; Conchita Izquierdo; Sergi Hernández; Sonia Broner; Carmen Muñoz-Almagro; Àngela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-09       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.